Immunocore Holdings plc (NASDAQ:IMCR) Receives $65.64 Consensus Target Price from Brokerages

Shares of Immunocore Holdings plc (NASDAQ:IMCR) have earned an average rating of “Moderate Buy” from the thirteen analysts that are covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and eight have issued a buy rating on the company. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $65.64.

A number of equities research analysts have recently weighed in on IMCR shares. Morgan Stanley reaffirmed an “equal weight” rating and set a $35.00 target price on shares of Immunocore in a research note on Friday, March 7th. Needham & Company LLC reiterated a “buy” rating and set a $71.00 target price on shares of Immunocore in a report on Wednesday, March 12th. Finally, HC Wainwright restated a “buy” rating and issued a $100.00 target price on shares of Immunocore in a research note on Wednesday, March 12th.

Insider Activity

In other news, Director Bros. Advisors Lp Baker purchased 807,338 shares of Immunocore stock in a transaction that occurred on Monday, March 17th. The stock was bought at an average price of $29.72 per share, with a total value of $23,994,085.36. Following the completion of the transaction, the director now directly owns 2,144,060 shares of the company’s stock, valued at approximately $63,721,463.20. The trade was a 60.40 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 9.10% of the company’s stock.

Institutional Trading of Immunocore

Institutional investors have recently added to or reduced their stakes in the business. GF Fund Management CO. LTD. bought a new position in shares of Immunocore during the fourth quarter valued at $25,000. China Universal Asset Management Co. Ltd. raised its position in Immunocore by 12.9% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 8,393 shares of the company’s stock worth $248,000 after buying an additional 960 shares during the last quarter. NEOS Investment Management LLC raised its position in Immunocore by 10.9% in the 4th quarter. NEOS Investment Management LLC now owns 11,194 shares of the company’s stock worth $330,000 after buying an additional 1,102 shares during the last quarter. Tema Etfs LLC bought a new position in Immunocore during the 4th quarter valued at about $330,000. Finally, Virtus ETF Advisers LLC grew its stake in shares of Immunocore by 39.0% in the fourth quarter. Virtus ETF Advisers LLC now owns 11,536 shares of the company’s stock worth $340,000 after acquiring an additional 3,238 shares during the period. 84.50% of the stock is currently owned by hedge funds and other institutional investors.

Immunocore Stock Performance

NASDAQ:IMCR opened at $29.81 on Friday. The company has a quick ratio of 3.76, a current ratio of 3.78 and a debt-to-equity ratio of 1.03. Immunocore has a twelve month low of $27.19 and a twelve month high of $66.00. The stock has a market cap of $1.49 billion, a P/E ratio of -31.38 and a beta of 0.79. The firm’s fifty day simple moving average is $29.99 and its 200 day simple moving average is $31.09.

About Immunocore

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.